Alzamend Neuro (ALZN) Receivables - Accured (2020)
Alzamend Neuro's (ALZN) quarterly Receivables - Accured came in at $77153.0 in Q2 2020.
Powered by 
Analysis
Alzamend Neuro (ALZN) Receivables - Accured (2020) Analysis & Trends
Alzamend Neuro has disclosed Receivables - Accured across 1 years of filings, most recently posting $77153.0 for Q2 2020.
- In Q2 2020, Receivables - Accured changed N/A year-over-year to $77153.0; the TTM figure through Apr 2020 stood at $77153.0 (changed N/A YoY), while the FY2020 annual figure was $77153.0, changed N/A from the prior year.
- Receivables - Accured came in at $77153.0 for Q2 2020 at Alzamend Neuro.
- In the past five years, Receivables - Accured ranged from a high of $77153.0 in Q2 2020 to a low of $77153.0 in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.51 Bn | 192.52 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.28 Bn | 176.11 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 131.06 Bn | 123.21 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.61 Bn | 73.62 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.71 Bn | 55.52 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.60 Bn | 48.46 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.41 Bn | 30.10 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.79 Bn | 30.50 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.11 Bn | 29.11 Bn | 1.16 Mn | 21.60 Mn |
| 10 | Alzamend Neuro | 5.57 Mn | 5.57 Mn | - | - |